Stock Research for MNOV

MNOV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MNOV Stock Chart & Research Data

The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MNOV Due diligence Resources & Stock Charts

The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNOV Detailed Price Forecast - CNN Money CNN View MNOV Detailed Summary - Google Finance
Yahoo View MNOV Detailed Summary - Yahoo! Finance Zacks View MNOV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MNOV Trends & Analysis - Trade-Ideas Barrons View MNOV Major Holders - Barrons
NASDAQ View MNOV Call Transcripts - NASDAQ Seeking View MNOV Breaking News & Analysis - Seeking Alpha
Spotlight View MNOV Annual Report - CompanySpotlight.com OTC Report View MNOV OTC Short Report - OTCShortReport.com
TradeKing View MNOV Fundamentals - TradeKing Charts View MNOV SEC Filings - Bar Chart
WSJ View Historical Prices for MNOV - The WSJ Morningstar View Performance/Total Return for MNOV - Morningstar
MarketWatch View the Analyst Estimates for MNOV - MarketWatch CNBC View the Earnings History for MNOV - CNBC
StockMarketWatch View the MNOV Earnings - StockMarketWatch MacroAxis View MNOV Buy or Sell Recommendations - MacroAxis
Bullish View the MNOV Bullish Patterns - American Bulls Short Pains View MNOV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MNOV Stock Mentions - StockTwits PennyStocks View MNOV Stock Mentions - PennyStockTweets
Twitter View MNOV Stock Mentions - Twitter Invest Hub View MNOV Investment Forum News - Investor Hub
Yahoo View MNOV Stock Mentions - Yahoo! Message Board Seeking Alpha View MNOV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MNOV - SECform4.com Insider Cow View Insider Transactions for MNOV - Insider Cow
CNBC View MNOV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNOV - OTC Markets
Yahoo View Insider Transactions for MNOV - Yahoo! Finance NASDAQ View Institutional Holdings for MNOV - NASDAQ


Stock Charts

FinViz View MNOV Stock Insight & Charts - FinViz.com StockCharts View MNOV Investment Charts - StockCharts.com
BarChart View MNOV Stock Overview & Charts - BarChart Trading View View MNOV User Generated Charts - Trading View




Latest Financial News for MNOV


MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
Posted on Monday August 06, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of MN-166 (ibudilast) in degenerative cervical myelopathy (DCM) in collaboration with the University of Cambridge. This clinical trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust.


MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
Posted on Tuesday July 31, 2018

The oral presentation entitled "Novel Composite Endpoint Extended Analysis during Extension of Ibudilast Phase 1b/2a Clinical Trial Better Predicts Post-Wash-Out Survival” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.


MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
Posted on Sunday July 29, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) is now fully enrolled with 35 subjects. This trial will measure the effect of MN-166 (ibudilast) on reducing brain microglial activation measured by positron emission tomography (PET) imaging using a biomarker and will also evaluate clinical outcomes in ALS subjects. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that this study is now fully enrolled.


MNOV: Plenty of Cash to Advance Pipeline Forward
Posted on Wednesday July 25, 2018

On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.